BAG6 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 colorectal adenocarcinoma line, engineered to disrupt the BAG6 gene. This loss-of-function model enables dissection of BAG6??s roles in protein quality control, apoptosis, and MHC class I antigen presentation without clonal homogeneity, reflecting a heterogeneous knockout pool suitable for population-level studies.
The HT29 cell line, a human epithelial colorectal adenocarcinoma, is a standard model for intestinal barrier function, oncogenic signaling, and drug response. These adherent cells express characteristic colorectal cancer markers and retain tumorigenic properties, making them ideal for studying pathway perturbations in a disease-relevant context. HT29 cells are responsive to inflammatory stimuli and chemotherapeutic agents, enabling investigation of tumor microenvironment interactions and drug resistance mechanisms.
BAG6 is a co-chaperone for HSP70 that directs misfolded proteins to ubiquitin-proteasomal degradation via interactions with HSP90, STUB1 (CHIP), and the proteasome, forming the BAG6-HSP70-STUB1-proteasome axis in ER-associated degradation (ERAD). In apoptosis, BAG6 interacts with TAJ (TNFRSF19) and DR5 (TNFRSF10B) to regulate caspase activity, while in antigen presentation, it cooperates with TAP for MHC class I loading. BAG6 expression is induced by ER stress through ATF6, IRE1??, and PERK, and by TNF-?? and IFN-??. Its downstream effects include modulation of caspase-3/7, NF-??B signaling, and MHC I surface expression.
In HT29 cells, BAG6 knockout disrupts proteostasis, leading to misfolded protein accumulation and altered ER stress responses. Impaired apoptosis under stress and reduced MHC I presentation mirror colorectal cancer immune evasion, providing a system to study tumor cell survival, protein quality control dysfunction, and immune recognition in the intestinal epithelium. The polyclonal knockout format offers a heterogeneous population that models mutation-driven variability, supporting the assessment of drug effects in a mixed genetic background.
Typical applications include western blotting and RT-qPCR for BAG6, Annexin V/propidium iodide apoptosis assays, ER stress induction with UPR gene analysis, MHC I flow cytometry, and co-immunoprecipitation of HSP70. Functional studies encompass proteasome inhibitor sensitivity, colony formation, and drug screening. This product supports research in colorectal cancer biology, protein quality control, immunopeptidome profiling, and ER stress-targeted therapeutics. For inquiries, contact Ascent Research.
